Citizens JMP analyst Silvan Tuerkcan upgraded Intellia Therapeutics (NTLA) to Outperform from Market Perform with a $33 price target The firm’s survey of North American allergist-immunologists highlights “strong interest in a once-and-done prophylactic therapy.” The results indicate an over 19% market share for Intellia’s NTLA-2002, or a $2.8B opportunity, the analyst tells investors in a research note. Citizens has confidence in the company’s Phase 3 data expected in the first half of 2026 and application submission timeline. It sees an attractive valuation and positive outlook for Intellia at current share levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- CoreWeave, NuScale, Southern Co, Intellia, and Prospect Capital: Insider Moves Unveiled!
- Private Markets: Cerebras raises $1B in pre-IPO funding round
- Unusually active option classes on open October 2nd
- Cathie Wood’s ARK Investment buys 99K shares of Intellia Therapeutics today
- Cathie Wood Boosts Stakes in Intellia and L3Harris, Cuts Kratos Holdings